about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsBiosensors and their applications - A review.Nanotheranostics for personalized medicineEnhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy.APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.Nanoparticle-Based Magnetic Resonance Imaging on Tumor-Associated Macrophages and Inflammation.Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theoryHigher expression of Bax in regulatory T cells increases vascular inflammation.Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancerAssessing intraepithelial neoplasia and drug safety in cancer-preventive drug development.Generation of a highly inducible Gal4-->Fluc universal reporter mouse for in vivo bioluminescence imagingExpression of TCTP antisense in CD25(high) regulatory T cells aggravates cuff-injured vascular inflammationAutomated tracking of quantitative assessments of tumor burden in clinical trials.A highly sensitive method for in vitro testing of fluorinated drug candidates using high-resolution continuum source molecular absorption spectrometry (HR-CS MAS).Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe (18) F-FITM.Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.Glucosamine-linked near-infrared fluorescent probes for imaging of solid tumor xenograftsNon-invasive in vivo imaging for liver tumour progression using an orthotopic hepatocellular carcinoma model in immunocompetent mice.Novel near-infrared fluorescent integrin-targeted DFO analogue.Two Photon Induced Luminescence of BSA Protected Gold Clusters.Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model.A design strategy for small molecule-based targeted MRI contrast agents: their application for detection of atherosclerotic plaques.
P2860
Q26740567-71D51762-48A0-4FB6-8D37-94ADA09097BAQ26748024-8F092FD2-882B-45AD-A833-62A288838330Q26851449-A4056DC3-E641-4BB4-BDFA-C66ABC56D1E2Q30452421-1B261277-F883-472E-9163-529F7305EE31Q33413085-D3967471-82BA-405C-B9A5-948D721D9D79Q33710955-D2F499C5-DE17-41E2-BAAC-6AD407AD914DQ33766595-21251A30-E5EB-48C5-8028-007AD614E72FQ34042974-313AAEDA-ADF0-4788-86AE-2D937122CC73Q34099721-A0030832-462F-4FFF-A092-39BCB777D932Q34334475-FC7649D4-5F1B-42F7-9847-07EF1000D210Q36849332-A21B6483-2D21-4157-9865-813041316A99Q36948953-E5D9E30A-C102-4C7F-8028-1E534B2BEB5FQ37225644-CACBACE9-13F5-4F40-AE22-4EE29B3FC9D3Q37721552-B9737416-0E7D-4039-B47D-4B4B62CFBE9EQ39001608-FAE28936-BCDF-40F2-8D7F-4768BC7D31A3Q39014061-CBA7B642-1AD1-45FF-A6C4-18440D82D815Q39428846-A626ADB3-BF96-4963-AE4D-5C7A4BCA769EQ39463185-2EEE2237-4BD4-4AF4-88F3-9AB843EF53A0Q39509049-39A3291E-1E6E-43C4-9364-ACA07BA956A3Q40044646-8A090ADB-BA15-4B80-9D84-54A50448A3C1Q40243670-FCEA9B08-7972-4E81-913D-2260F6D36724Q47712079-77B5F907-814A-4BE8-A43C-196B10BB737DQ51057792-7B59BCBC-EF8F-4504-9EB3-BB637267A663
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Imaging and oncologic drug development.
@ast
Imaging and oncologic drug development.
@en
type
label
Imaging and oncologic drug development.
@ast
Imaging and oncologic drug development.
@en
prefLabel
Imaging and oncologic drug development.
@ast
Imaging and oncologic drug development.
@en
P356
P1476
Imaging and oncologic drug development
@en
P2093
Caroline C Sigman
Gary J Kelloff
P304
P356
10.1200/JCO.2006.06.5623
P407
P577
2006-07-01T00:00:00Z